このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Formycon バランスシートの健全性

財務の健全性基準チェック /16

Formyconの総株主資本は€502.8M 、総負債は€20.5Mで、負債比率は4.1%となります。総資産と総負債はそれぞれ€890.4Mと€387.6Mです。

主要情報

4.1%

負債資本比率

€20.54m

負債

インタレスト・カバレッジ・レシオ	n/a
現金	€27.04m
エクイティ	€502.75m
負債合計	€387.61m
総資産	€890.36m

財務の健全性に関する最新情報

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19

Recent updates

Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares

May 29

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

May 03

Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S

Jan 19

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

Dec 23

Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up

Sep 26

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Sep 04

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Jul 13

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Jun 02

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

May 23

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Jan 04

財務状況分析

短期負債: FYBの短期資産 ( €67.1M ) は短期負債 ( €69.3M ) をカバーしていません。

長期負債: FYBの短期資産 ( €67.1M ) は長期負債 ( €318.3M ) をカバーしていません。

デット・ツー・エクイティの歴史と分析

負債レベル: FYB総負債よりも多くの現金を保有しています。

負債の削減: FYBの負債対資本比率は、過去 5 年間で0%から4.1%に増加しました。

債務返済能力: FYBの営業キャッシュフローはマイナスであるため、負債は十分にカバーされていません。

インタレストカバレッジ: FYBの負債に対する利息支払いが EBIT によって十分にカバーされているかどうかを判断するにはデータが不十分です。

Formycon バランスシートの健全性

財務の健全性 基準チェック /16

主要情報

財務の健全性に関する最新情報

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

Recent updates

Investor sentiment improves as stock rises 16%

Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares

Price target decreased by 8.7% to €87.00

We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 7.9% to €103

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S

We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 146%

Price target decreased by 8.6% to €116

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Consensus forecasts updated

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Consensus revenue estimates increase by 13%

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Consensus revenue estimates fall by 17%

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Price target decreased to €70.00

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Consensus forecasts updated

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Consensus forecasts updated

Full year 2020 earnings released

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

New 90-day high: €75.20

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Price target raised to €46.45

New 90-day high: €46.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Analysts update estimates

New 90-day high: €32.00

財務の健全性基準チェック /16